Cardio Round-Up: Inappropriate Oral Anticoagulation Doses, Post-Systolic Shortening in CAD; and More Cardiology Research

Practice Tips with Dr. Lichaa: Perforated Balloon No Reflow

Hady Lichaa, MD, FACC, FSCAI, FSVM, RPVI, is an assistant professor of medicine at the University of Tennessee College of Medicine, and an interventional cardiologist specializing in complex coronary interventions. Dr. Lichaa is a content partner for DocWire News and contributes interventional content several times per month to DocWire News. In this edition of his Practice Tips series, Dr. Lichaa describes the perforated balloon technique for coronary no reflow, which stands as one of the most challenging things for interventional cardiologists to deal with.

Advertisement

Prior Treatment Doses in Patients with Stroke After Oral Anticoagulation Therapy

Danish cardiologists, led by Naja E. Vinding, MD, investigated prior treatments in patients with AFib who experienced first-time stroke after OAC therapy, and asserted that “half of the patients with atrial fibrillation with stroke were on inappropriate OAC therapy.”

Prognosis with Post-Systolic Shortening in Patients with Stable Coronary Artery Disease

Researchers assessed the predictive value of post-systolic shortening (PSS) for early identification of myocardial dysfunction in patients with stable coronary artery disease (CAD). Using speckle tracking automated functional imaging (AFI), researchers, led by Shirui Lu, determined that PSS was an independent predictor for adverse events in patients with stable CAD with preserved systolic function.

The Time is Now: Sex Disparities Persist in Ischemic Heart Disease

Cardiovascular disease is the leading cause of death among women in the United States. However, clinical trials in interventional cardiology remain plagued by inadequate enrollment and retention of women relative to the sex-based prevalence of ischemic heart disease. Further, trials remain inadequately powered to detect sex-based differences in health outcomes. Growing awareness of sex-based differences in cardiovascular disease over the past decade has prompted efforts to delineate mechanistic factors, whether biologic or social, underlying observed differences.